Evidence method
Sequential · gp.financial.deposits
-20.31% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
GDOT · Jun 30, 2021
GREEN DOT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001386278-21-000039Bank
Evidence method
Yoy · gp.fundamentals.net_income
656.92% · CORE · VALID
Evidence method
Level · gp.fundamentals.cash
$1.9B · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Jun 30, 20213/3 normalizedLevel 3Dec 31, 20213/3 normalizedLevel 3Mar 31, 20223/3 normalizedLevel 3Jun 30, 20223/3 normalizedLevel 3Sep 30, 20224/4 normalizedLevel 3Dec 31, 20223/3 normalizedLevel 3Mar 31, 20234/4 normalizedLevel 3Jun 30, 20234/4 normalizedLevel 3Sep 30, 20234/4 normalizedLevel 3Dec 31, 20234/4 normalizedLevel 3Mar 31, 20244/4 normalizedLevel 3Jun 30, 20244/4 normalizedLevel 3Sep 30, 20243/3 normalizedLevel 3Dec 31, 20244/4 normalizedLevel 3Mar 31, 20254/4 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20264/4 normalizedLevel 3Jun 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 31.44%
- Current
- -20.31%
- Delta
- -51.75%
- Previous
- -45.06%
- Current
- 656.92%
- Delta
- 701.99%
- Previous
- $2.7B
- Current
- $1.9B
- Delta
- -$820.7M
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.